Anti-PD1 immunotherapy improves outcomes for patients with metastatic cutaneous squamous cell carcinoma (cSCC). But we need to know more about who will, or will not, respond adequately.

Anti-PD1 immunotherapy improves outcomes for patients with metastatic cutaneous squamous cell carcinoma (cSCC). But we need to know more about who will, or will not, respond adequately.

CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus remains on what defines high-risk disease, according to Travis W.

Waiting to treat squamous cell skin cancer also increases the risk of hurting your appearance and leading ... Sometimes we recommend radiation after surgery to destroy tumor cells that may have been ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

Survivors of blood or marrow transplant had increased risk for subsequent cutaneous malignant neoplasms. Basal cell carcinoma occurred more frequently than squamous cell carcinoma or melanoma.